OmniaBio Inc., a subsidiary of Toronto-based CCRM, is a contract development and manufacturing organization (CDMO) producing gene-modified cells and viral vectors, compliant with current Good Manufacturing Practices (cGMP) standards. OmniaBio is operational and offering CDMO services now.

At a planned 400,000 square feet, OmniaBio will be the largest CDMO exclusively manufacturing for cell and gene therapies in Canada. It is expected to catalyze life sciences jobs and innovation in Ontario while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson’s and diabetes.

Find out more about our existing and upcoming manufacturing infrastructure.

Contact us to learn more about how we can support your needs at cdmo@omniabio.com.